In various cancer types, including gastric, prostate, urothelial, breast, and vulvar, elevated expression of CFL-1 and its regulators, LIMK1/SSH1, have been implicated in tumor progression and aggressiveness, as well as in poor survival rate [10–16]. Here, LIMK1 is linked to neoplasm.